Navigation Links
MedImmune Submits Biologics License Application to FDA for Motavizumab
Date:2/4/2008

GAITHERSBURG, Md., Feb. 4 /PRNewswire/ -- MedImmune announced today it submitted to the U.S. Food & Drug Administration (FDA) on January 30 a Biologics License Application (BLA) for motavizumab, an investigational monoclonal antibody (MAb) derived from recombinant DNA technology. The motavizumab BLA is supported by clinical trial data from more than 6,000 patients in which safety and efficacy in prevention of serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients were evaluated.

"We are pleased to submit this BLA for motavizumab, which we believe represents another tool in the fight against RSV. This marks a significant milestone for this molecule and further reinforces MedImmune's commitment to developing anti-RSV biologics for the underserved pediatric patient population," said Linda J. Peters, senior vice president, regulatory affairs.

Motavizumab was studied in an active-controlled Phase 3 trial against the standard of care in pediatric patients at high risk of serious RSV disease. Primary and secondary endpoints of the study included incidence of RSV hospitalizations and RSV-specific medically attended outpatient lower respiratory tract infections. Rates of adverse events, serious adverse events and study drug discontinuations were balanced between treatment groups. The most frequently observed reactions versus the active comparator were cutaneous reactions (overall).

"Beyond the findings of the various investigational trials for motavizumab, we believe this molecule will help reinforce the positive role that MAbs play in RSV prevention within the current clinical body of evidence. It also reinforces our position as a leader in RSV prevention," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease.

RSV is a leading cause of viral respiratory infection among infants. Each year, up to an estimated 125,000 infants in the United States are hospitalized with sev
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
2. MedImmune Announces Seven Key Promotions and New Hires
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
6. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
7. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Cephalon Submits Supplemental New Drug Application for FENTORA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ntario, Nov. 24 Dow Agro...e assets of Hyland Seeds, a division of Thompsons ...nd Seeds will further expand Dow AgroSciences, cur... introduction of SmartStax(TM) in 2010 and D...y in corn in 2012. The transactional close is expe...
(Date:11/24/2009)...4 /PRNewswire-Asia/ -- NOD Pharmaceuticals Inc. an... has allowed the patent application for,its nano-p... NOD technology is a highly efficient approach to...e nano-particles to enable oral delivery of drugs,...gy is a platform technology,that can be applied to...
(Date:11/24/2009)...endpoint has been met for patients with advanced-s...UEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEter...Company"), a global biopharmaceutical company focu...nced positive efficacy data from a Phase 2 study w...-108 (formerly AN-152), in patients with advanced ...
(Date:11/24/2009)...vember 24 Health Robotics today an...nture with a group of selected,investors. This rec...der the,name Health Robotics Canada, Inc. and will.... Room of the Future concept, which includes the,r...v.SOFT(TM), and OMM(TM).,Health Robotics Canada In...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...ounced,today that it has been awarded a $12.9 mill...and Infectious Diseases (NIAID), a part of the US,...ense research in the area,of infectious disease bi...r a five-year period, Caprion,will act as one of t...s,Disease & Biodefense, and will employ its distin...
...09 for $5,000 each, MOUNTAIN VIEW, Calif., Oct. 6... genome sequencing company, today announced its,fo...-scale human genome,sequencing services., The com...n operating in,"stealth mode" from a 32,000-square...o and a half years, Complete Genomics has been rei...
...ment resulting from years of, study by leading r..., Del-Immune V, BOUL...at,the EUPROBIO 2008 Conference, an abstract entit...nduction and its impact on cytotoxicity of,natural...searchers and,educators. Attendees to the presenta...
Other Biology Technology:Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract 2Complete Genomics Launches, Becomes World's First Large-Scale Human Genome Sequencing Company 2Complete Genomics Launches, Becomes World's First Large-Scale Human Genome Sequencing Company 3Complete Genomics Launches, Becomes World's First Large-Scale Human Genome Sequencing Company 4EUPROBIO 2008 Presentation to Highlight Latest Immune Research 2
(Date:11/26/2009)...nt Staphylococcus Aureus ) and other drug-resista...ture plasma prototype devices have been developed ...dal cocktails. , Two prototype devices have been...thy skin (e.g. hands and feet) in hospitals and pu...t; and another to shoot bacteria-killing agents in...
(Date:11/25/2009)...ters, police officers and ambulance workers faced ...er complex. They battled to save people from the c...kled fires and evacuated as many people as they co... people. And making their jobs even harder was the...s and their relatives jammed mobile networks with ...
(Date:11/25/2009)... assistant professors recently received funding fr...ue research beneficial to understanding the enviro...opher Blackwood, assistant professor in the Depart... support two separate research projects. , His f... Communities and Functions from the Leaf to the La...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Hologic to Release Third Quarter Fiscal 2009 Operating Results on Monday August 3 2009 51476 1Hologic to Release Third Quarter Fiscal 2009 Operating Results on Monday August 3 2009 51476 2Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 1Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 2Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 3Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 4Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 5Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 6Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 7Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 8Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 9Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Virginia AARP Members 51473 10Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 51468 1Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 51468 2Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 51468 3
...ntists at the University of Liverpool have found h... spread of cancer cells. , Researchers discovered ...eld around cancer cells and prevents them from cau...tein that exists in the blood. , In diseases su... cells lose growth control and eventually form tum...
...n bone marrow has been used to create early-stage ...forward that will help researchers understand more...h published today (Friday, April 13 2007), in the ... carried out in Germany* by a team of scientists l...iversity of Göttingen but now of the North-east En...
...to growers are likely to soon be able to cultivate...ides against grey mould (Botrytis cinerea). This i...chard Finkers from Wageningen University, with whi... Finkers designed highly efficient methods whereby...The leading company De Ruiter Seeds is already app...
Other Biology News:Scientists discover how body fights to control spread of cancer 2Early-stage sperm cells created from human bone marrow 2Research on grey mould offers possible breakthrough in tomato cultivation 2
Single Pass DNA Sequencing from Agencourt Bioscience
...naround sequencing of individual research samples,...lasmids. Agencourt's world-class, high performance...ed20 bases per day. The key benefits of Agencourt...e 24 48 hour sample turnaround, industry leading ...
Full-Length "Primer Walk" Sequencing from Seqwright
Goat Anti-Wnt2 Polyclonal Antibody, Unconjugated from MBL International
Biology Products: